These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 36059939)

  • 1. A single-dose, randomized, open-labeled, parallel-group study comparing the pharmacokinetics, pharmacodynamics and safety of leuprolide acetate microspheres 3.75 mg and Enantone
    Hu X; Zhang Q; Zheng Y; Zhai Y; Xu N; Zhao Q; Liu J; Wan L; Luo J
    Front Pharmacol; 2022; 13():946505. PubMed ID: 36059939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers.
    Zhou H; Xie J; Zhu X; Li X; Yu X; Zhang Y; Su Y; He C; Zhu M; Li XL; Liu Y; Chen J; Cheng D; Chen M; Wang Y; Ge Q; Fan L; Wang Y; Shao Z; Liu B; Shan R; Dai X; Wang H; Wang H
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1149-1156. PubMed ID: 34372746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence and Safety Assessment of Two Formulations of Metformin Hydrochloride Sustained-Release Tablets (Yuantang
    Sun ML; Liu HJ; Luo XD; Wang Y; Zhang W; Liu C; Wang X
    Drugs R D; 2022 Mar; 22(1):51-60. PubMed ID: 35061235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats.
    Lee DS; Kim SJ; Choi GW; Lee YB; Cho HY
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29662027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza
    Mai G; Fan L; Li M; Zhang P; Gan C; Huang Q; Shentu J
    Front Pharmacol; 2020; 11():610880. PubMed ID: 33584289
    [No Abstract]   [Full Text] [Related]  

  • 7. Bioequivalence of a biosimilar enoxaparin sodium to Clexane
    Martínez González J; Monreal M; Ayani Almagia I; Llaudó Garín J; Ochoa Díaz de Monasterioguren L; Gutierro Adúriz I
    Drug Des Devel Ther; 2018; 12():575-582. PubMed ID: 29593380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
    Singh I; Attrey A; Garg A; Patel R; Jose V
    Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references.
    Leitner JM; Mayr FB; Spiel AO; Firbas C; Savulsky C; Mis R; Corrado ME; Jilma B
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):407-14. PubMed ID: 18793582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose bioequivalence: Exploration of eligible protocol design.
    Que L; Huang K; Ding Y; Chu N; Yang J; Qian Z; He Q
    J Clin Pharm Ther; 2021 Apr; 46(2):492-503. PubMed ID: 33325562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects.
    Huang K; Que L; Ding Y; Chu N; Qian Z; Shi Y; Qin W; Li Z; Chen Y; Gu X; Wang J; Zhang L; Zhang J; Zhu X; Yang Y; Tang Y; He Q
    Front Pharmacol; 2021; 12():694375. PubMed ID: 34220519
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
    Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
    Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
    Lim CN; Salem AH
    Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic comparison of subcutaneous
    Saltzstein D; Shore ND; Moul JW; Chu F; Concepcion R; de la Motte S; McLane JA; Atkinson S; Yang A; Crawford ED
    Ther Adv Urol; 2018 Feb; 10(2):43-50. PubMed ID: 29434672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial.
    Li Y; Qi L; Bai H; Liu Y; Fan R; Tu Y; Sun Y; Wang J; Qi Q; Feng X; Zhou D; Wang X
    Front Pharmacol; 2020; 11():571747. PubMed ID: 33364947
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of Level A In Vitro-Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation.
    Lee DS; Kang DW; Choi GW; Choi HG; Cho HY
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31906491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer.
    Mostafa NM; Chwalisz K; Larsen L; Mattia-Goldberg C; Spitz A; Pradhan RS
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):270-5. PubMed ID: 27128832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.